Care management reduces depression and suicidal thoughts in older primary care patients
Depression in older adults too often goes unrecognized
and untreated, resulting in untold misery, worsening of medical illness, and early
death. A new study has identified one important remedy: Adding a trained depression
care manager to primary care practices can increase the number of patients receiving
treatment, lead to a higher remission rate of depression, and reduce suicidal
thoughts.
The two-year outcomes of the multicenter Prevention of
Suicide in Primary Care Elderly: Collaborative Trial (PROSPECT) are published
online in the American Journal of Psychiatry.
Lead author of the study is Dr. George S. Alexopoulos,
director of the Institute of Geriatric Psychiatry at NewYork-Presbyterian Hospital/Westchester
Division and professor of psychiatry at Weill Cornell Medical College.
"Almost one in 10 older adults in the United States
has some form of depression, and one-fifth among them contemplates suicide. Two-thirds
of these patients are treated by primary care physicians. Sadly, their depression
is often inadequately treated due to the primary care physician's time constraints
and the patient's reluctance to discuss their symptoms and adhere to treatment,"
says Dr. Alexopoulos. "The critical finding of the PROSPECT study is that
adding a trained care manager to primary care practices increases the number of
depressed older patients who receive treatment and improves their outcomes, not
only in the short term, but over two years.
"This is important because depression can either
become chronic or relapse after an initial improvement," adds Dr. Alexopoulos.
"Most diseases have worse outcomes when an old person becomes depressed.
Depression almost doubles the risk for death. It follows that treating depression
effectively can reduce sickness, disability and death."
The study, conducted by New York Presbyterian/Weill Cornell,
the University of Pittsburgh, and the University of Pennsylvania, followed 599
patients aged 60 years and older with depression at 20 primary care practices
of varying sizes in New York and Pennsylvania. Participants were randomized to
receive either the PROSPECT intervention or usual care. Those in the PROSPECT
group were assigned a care manager -- a trained social worker, nurse or psychologist
-- who helped the physician offer treatment according to accepted practice guidelines,
monitored treatment response and provided follow-up over two years. Practice guidelines
included the antidepressant citalopram, with the option of other drugs or psychotherapy.
After two years, nearly 90 percent of patients in the
PROSPECT care management group had received treatment for depression, compared
with 62 percent of those receiving usual care by their physicians. The decline
in suicidal ideation was 2.2 times greater in the PROSPECT group.
Remission of depression happened faster in the PROSPECT
intervention group and remission rates continued to increase between months 18
and 24, while no appreciable increase occurred in the usual care group during
the same period.
The PROSPECT intervention worked especially well for
a subgroup of patients with major depression, the more severe form of the disease,
with a greater number achieving remission, or the near absence of symptoms. Patients
with minor depression had favorable outcomes regardless of their study group.
Various forms of care management are being used successfully
for cardiovascular patients needing anticoagulation medication and for diabetes
patients needing insulin monitoring, says Dr. Alexopoulos. "The PROSPECT
study has demonstrated that care management is highly successful for older adults
with major depression."
Dr. Alexopoulos serves as a paid member of the speaker's
bureau and a paid member of the Scientific Advisory Board for Forest Laboratories
Inc., the maker of the antidepressant drug citalopram. Forest offered free citalopram
and a small stipend to support the study.
Co-authors include Drs. Martha L. Bruce and Patrick J.
Raue of NewYork-Presbyterian/Westchester and Weill Cornell Medical College; Dr.
Charles F. Reynolds III of the University of Pittsburg; Drs. Ira R. Katz, David
W. Oslin and Thomas Ten Have of the University of Pennsylvania; and Dr. Benoit
H. Mulsant of the University of Toronto.
|